Better Medicines Created Rapidly Through De Novo Protein Design

• Demonstrating that miniproteins are a powerful, stable therapeutic modality with high-affinity, specific binding
• Discussing development using a combination of de novo design, synthetic biology, and laboratory automation
• Creating a toolbox of modular miniprotein domains with ideal drug-like and developability profiles

Speakers:

Ben Meinen

Head, Protein Design & Investigator

AI Proteins